ImmunoBrain Checkpoint
Biopharmaceutical company targeting neurodegeneration and aging by modulating the immune system.
About
Technology stack
detected 2026-06-09No comments yet. Be the first to share your take.
What does ImmunoBrain Checkpoint do?
ImmunoBrain Checkpoint is a biopharmaceutical company pioneering a transformative approach to treating neurological disorders by harnessing the power of the peripheral immune system to mitigate brain pathology. Their lead program, IBC-Ab002, is a novel anti-PD-L1 antibody currently being investigated in patients with early Alzheimer's disease. They aim to redefine the treatment of neurological disorders by targeting the peripheral immune system to benefit the brain.
How much funding has ImmunoBrain Checkpoint raised?
ImmunoBrain Checkpoint has raised a total of $10M in funding. The most recent round on record is Seed.
Where is ImmunoBrain Checkpoint headquartered?
ImmunoBrain Checkpoint is headquartered in Tel Aviv, Israel.
When was ImmunoBrain Checkpoint founded?
ImmunoBrain Checkpoint was founded in 2016.
What industry does ImmunoBrain Checkpoint operate in?
ImmunoBrain Checkpoint operates in Healthcare, Immunology, Immunotherapy, Alzheimers, Neurology, Biopharmaceutical.
How many employees does ImmunoBrain Checkpoint have?
ImmunoBrain Checkpoint has approximately 18 people on record.